KEY vs TRDA · P/E 13, rev $7.51B vs P/E 12, rev $210.8M
KeyCorp (KEY) versus Entrada Therapeutics Inc (TRDA) — a side-by-side from cached financials, not a winner call.
KeyCorp (KEY) is a banks - regional company listed on US.
Entrada Therapeutics Inc (TRDA) is a biotechnology company listed on US.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Latest reported TRDA revenue for 2024-12-31 was $210.8M. Net income was $65.6M. Revenue was up 63.4% from 2023-12-31 to 2024-12-31. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
KEY currently screens at market cap $22.64B and trailing P/E 12.8. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
Not investment advice. Open the KEY and TRDA stock pages for the full models.
Not investment advice.